Key facts
- Metagen Therapeutics’s last known valuation is $54.2M (Jan 2026).
- It has raised $36.5M; the latest was Later Stage VC ($22.4M) in Jan 2026.
- Notable investors include Global Brain, SMBC Venture Capital, Mizuho Capital, J-Startup, JIC Venture Growth Investments — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Metagen Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Metagen Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Metagen Therapeutics
Operator of microbiome therapeutics and manufacturing platform intended to advance precision treatment using fecal microbiota transplantation. The company offers GMP-compliant manufacturing, paired metagenomic datasets, and AI-driven donor-recipient matching, enabling clinicians and biopharmaceutical researchers, to develop targeted microbiome-based therapies across multiple disease areas.
- Sector
- Healthcare
- HQ
- Tsuruoka, Japan
- Founded
- 2020
- Employees
- 50
- Website
- metagentx.com/
- Ownership
- Privately Held (backing)
Metagen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Metagen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Metagen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.